Skip to main content
. 2013 May 27;104(7):912–919. doi: 10.1111/cas.12172

Table 2.

Number of patients who entered each cycle and comparison with the VISTA study

Cycle no. 1.3 mg/m2 dose level in the current study (n = 87) n (%) The global VISTA study (n = 340) n (%)
1 87 (100) 340 (100)
2 73 (84) 305 (90)
3 63 (72) 284 (83)
4 50 (57) 266 (78)
5 44 (51) 249 (73)
6 39 (45) 236 (69)
7 37 (43) 224 (65)
8 33 (38) 213 (62)
9 28 (32) 202 (59)

VISTA, Velcade as Initial Standard Therapy in Multiple Myeloma.